BALSARI, ANDREA
 Distribuzione geografica
Continente #
AS - Asia 9.809
EU - Europa 9.471
NA - Nord America 9.109
SA - Sud America 869
AF - Africa 192
OC - Oceania 65
Continente sconosciuto - Info sul continente non disponibili 12
Totale 29.527
Nazione #
US - Stati Uniti d'America 8.746
CN - Cina 3.806
GB - Regno Unito 2.993
SG - Singapore 2.495
IT - Italia 1.575
DE - Germania 1.044
SE - Svezia 868
HK - Hong Kong 795
RU - Federazione Russa 681
BR - Brasile 623
IN - India 555
VN - Vietnam 504
FR - Francia 429
TR - Turchia 339
UA - Ucraina 336
KR - Corea 325
NL - Olanda 290
IE - Irlanda 263
BD - Bangladesh 254
JP - Giappone 249
FI - Finlandia 236
CA - Canada 233
ES - Italia 146
DK - Danimarca 140
EU - Europa 116
ID - Indonesia 110
PL - Polonia 109
GR - Grecia 92
CO - Colombia 91
BE - Belgio 87
MX - Messico 80
TW - Taiwan 67
AU - Australia 58
CI - Costa d'Avorio 56
AR - Argentina 52
PH - Filippine 39
IR - Iran 34
PT - Portogallo 34
EG - Egitto 28
IQ - Iraq 28
VE - Venezuela 27
ZA - Sudafrica 27
TH - Thailandia 26
CH - Svizzera 24
EC - Ecuador 22
AT - Austria 21
LV - Lettonia 21
RO - Romania 21
CL - Cile 19
MY - Malesia 19
KE - Kenya 18
SA - Arabia Saudita 18
MA - Marocco 16
PK - Pakistan 16
JO - Giordania 14
AE - Emirati Arabi Uniti 13
HU - Ungheria 13
IL - Israele 13
PE - Perù 13
UZ - Uzbekistan 12
CR - Costa Rica 10
CY - Cipro 9
DZ - Algeria 9
NP - Nepal 9
NG - Nigeria 8
UY - Uruguay 8
AZ - Azerbaigian 7
SK - Slovacchia (Repubblica Slovacca) 7
DO - Repubblica Dominicana 6
JM - Giamaica 6
KZ - Kazakistan 6
PY - Paraguay 6
TT - Trinidad e Tobago 6
AL - Albania 5
BH - Bahrain 5
CZ - Repubblica Ceca 5
MO - Macao, regione amministrativa speciale della Cina 5
NO - Norvegia 5
NZ - Nuova Zelanda 5
PA - Panama 5
TN - Tunisia 5
AM - Armenia 4
BO - Bolivia 4
EE - Estonia 4
ET - Etiopia 4
HN - Honduras 4
LA - Repubblica Popolare Democratica del Laos 4
LU - Lussemburgo 4
PS - Palestinian Territory 4
QA - Qatar 4
A2 - ???statistics.table.value.countryCode.A2??? 3
BY - Bielorussia 3
GE - Georgia 3
GT - Guatemala 3
KG - Kirghizistan 3
KW - Kuwait 3
LB - Libano 3
LK - Sri Lanka 3
MD - Moldavia 3
RS - Serbia 3
Totale 29.582
Città #
Southend 2.698
Singapore 1.420
Chandler 794
Ashburn 770
Hong Kong 686
Milan 649
Beijing 532
Seattle 486
San Jose 460
Fairfield 386
Frankfurt am Main 354
Princeton 335
Wilmington 328
Ann Arbor 293
Dallas 292
Council Bluffs 254
Dublin 254
Guangzhou 254
Los Angeles 250
Jacksonville 233
Santa Clara 205
Houston 201
Woodbridge 201
Shanghai 199
Nanjing 195
Redmond 179
Dearborn 172
Bengaluru 148
Mountain View 144
Lauterbourg 141
Cambridge 140
Toronto 124
Ho Chi Minh City 123
Grafing 117
Boardman 108
Moscow 107
Des Moines 105
Hanoi 104
Sakarya 103
Tokyo 99
Athens 93
New York 92
Hangzhou 90
Buffalo 89
Helsinki 89
Shenyang 87
Columbus 82
Tianjin 81
Warsaw 81
Phoenix 79
Shenzhen 79
Hefei 77
Jinan 77
Jakarta 74
The Dalles 73
Bogotá 72
Changsha 71
Andover 70
Serra 70
Zhengzhou 67
Wuhan 62
São Paulo 61
Somerville 59
Chengdu 58
Nanchang 57
Abidjan 56
Brussels 56
Seoul 52
Redwood City 48
Cangzhou 46
Istanbul 46
Berlin 44
Hebei 44
Fuzhou 43
Rome 40
Mumbai 37
Munich 37
Nuremberg 34
Dong Ket 33
Turin 33
Bitonto 32
Madrid 31
San Diego 31
Taipei 31
Sunnyvale 30
Ningbo 25
San Francisco 24
Boston 23
Haiphong 22
Jiaxing 22
London 22
Norwalk 22
Central 21
Kunming 21
Ottawa 21
Xiamen 21
Atlanta 20
Chicago 20
Fremont 20
Palermo 20
Totale 17.661
Nome #
Gut microbiota condition the therapeutic efficacy of trastuzumab in HER2-positive breast cancer 3.042
Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-Small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade 943
Modulation of Pulmonary Microbiota by Antibiotic or Probiotic Aerosol Therapy: A Strategy to Promote Immunosurveillance against Lung Metastases 488
Local Administration of Caloric Restriction Mimetics to Promote the Immune Control of Lung Metastases 371
Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors 349
Anti-tumor activity of CpG-ODN aerosol in mouse lung metastases 344
The lung microbiota: role in maintaining pulmonary immune homeostasis and its implications in cancer development and therapy 330
Activation of enteroendocrine cells via TLRs induces hormone, chemokine, and defensin secretion 302
Sodium glucose cotransporter 1 ligand BLF501 as a novel tool for management of gastrointestinal mucositis 301
Increased sensitivity to chemotherapy induced by CpG-ODN treatment is mediated by microRNA modulation 287
Toll-like receptors 3, 4, and 7 are expressed in the enteric nervous system and dorsal root ganglia 285
HER2 signaling regulates the tumor immune microenvironment and trastuzumab efficacy 281
Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don’t) know 281
Abstract in rivista: Role of Toll-like receptor 9 (TLR-9) in acute graft-versus-host disease 265
Degranulation of paneth cells via toll-like receptor 9 265
Aerosol 1,25-dihydroxyvitamin D3 supplementation: A strategy to boost anti-tumor innate immune activity 265
Sodium-dependent glucose transporter-1 as a novel immunological player in the intestinal mucosa 263
Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration 261
Exploiting poly(I:C) to induce cancer cell apoptosis 261
TLR9-agonists oppositely modulate DNA-repair genes in tumor versus immune cells and enhance chemotherapy effects 255
Low molecular weight hyaluronic acid increases the self-defense of skin epithelium by induction of beta-defensin 2 via TLR2 and TLR4 253
Poly(I:C) and CpG-ODN combined aerosolization to treat lung metastases and counter the immunosuppressive microenvironment 251
Effect of adjuvant trastuzumab treatment in conventional clinical setting : an observational retrospective multicenter Italian study 250
Low molecular weight hyaluronic acid increases the self defence of skin epithelium by induction of β-defensin 2 via TLR2 and 4 247
Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition 247
miR-302b enhances breast cancer cell sensitivity to cisplatin by regulating E2F1 and the cellular DNA damage response 244
High efficacy of CpG-ODN, cetuximab and cisplatin combination for very advanced ovarian xenograft tumors 237
Toll-like receptor 3 as a new marker to detect high risk early stage Non-Small-Cell Lung Cancer patients 233
Antitumor efficacy of trastuzumab in nude mice orthotopically xenografted with human pancreatic tumor cells expressing low levels of HER-2/neu 229
Caveolin-1 is expressed on multipotent cells of hair follicles and might be involved in their resistance to chemotherapy 229
The influence of a fatty acids-free diet on breast cancer development in FVB/neu transgenic mice 229
Cross-talk among Toll-like receptors and their ligands 228
CpG-oligodeoxynucleotides induce mobilization of hematopoietic progenitor cells into peripheral blood in association with mouse KC (IL-8) production 228
Critical role of TLR9 in acute graft-versus-host disease 228
Activation of NK cell cytotoxicity by aerosolized CpG-ODN/poly(I:C) against lung melanoma metastases is mediated by alveolar macrophages 228
Macrophages impair TLR9 agonist antitumor activity through interacting with the anti-PD-1 antibody Fc domain 228
Therapeutic synergism of gemcitabine and CpG-oligodeoxynucleotides in an orthotopic human pancreatic carcinoma xenograft 225
SGLT-1 as a novel immunological player in the intestinal mucosa 224
Toll-like receptor agonists regulate β-defensin 2 release in hair follicle 221
Doxorubicin-induced alopecia is associated with sebaceous gland degeneration 221
EGFR through STAT3 modulates ΔN63α expression to sustain tumor-initiating cell proliferation in squamous cell carcinomas 221
The 67 kDa laminin receptor increases tumor aggressiveness by remodeling laminin-1 218
Ascites regression and survival increase in mice bearing advanced-stage human ovarian carcinomas and repeatedly treated intraperitoneally with CpG-ODN 218
Activation of smooth muscle and myenteric plexus cells of jejunum via Toll-like receptor 4 210
Influence of fatty acid-free diet on mammary tumor development and growth rate in HER-2/neu transgenic mice 210
COMPUESTOS GLUCOPIRANOSIDOS UTILES PARA TRATAR DIABETES MELLITUS, ENFERMEDADES INFLAMATORIAS Y/O ALERGICAS, Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN 210
Allostimulation of patients' lymphocytes generates both T and NK-like cells cytotoxic for autologous melanoma 209
Antibody response after vaccination with antigen-pulsed dendritic cells 207
Epithelium-mesenchyme compartment interaction and oncosis on chemotherapy-induced hair damage 206
Stimulation of TLRs by LMW-HA induces self-defense mechanisms in vaginal epithelium 205
Induction of Paneth cell degranulation by orally administered toll-like receptor ligands 204
Aerosol delivery in the treatment of lung cancer 204
Neoplastic and stromal cells contribute to an extracellular matrix gene expression profile defining a breast cancer subtype likely to progress 203
Induction of pro-inflammatory programs in enteroendocrine cells by the Toll-like receptor agonists flagellin and bacterial LPS 202
Antitumor activity of the TLR-5 ligand flagellin in mouse models of cancer 201
Compound with glycidic structure active in the therapy of systemic and local inflammation 199
CpG-oligodeoxynucleotides exert remarkable antitumor activity against diffuse malignant peritoneal mesothelioma orthotopic xenografts 199
Expression and prognostic significance of the autoimmune regulator gene in breast cancer cells 198
Low molecular weight hyaluronic acid increases the self defence of skin epithelium by induction of β-defensin 2 via TLR2 and 4 197
Critical role of Toll-like receptor 9 in acute graft-versus-host disease 196
Absence of the CD1 molecule up-regulates antitumor activity induced by CpG oligodeoxynucleotides in mice 196
Inhibition of DNA Repair Mechanisms and Induction of Apoptosis in Triple Negative Breast Cancer Cells Expressing the Human Herpesvirus 6 U94 196
COMPOUNDS WITH GLYCIDIC STRUCTURE ACTIVE IN THE THERAPY OF SYSTEMIC AND LOCAL INFLAMMATION 194
Combination of a CpG-oligodeoxynucleotide and a topoisomerase I inhibitor in the therapy of human tumour xenografts 193
PDGFRβ and FGFR2 mediate endothelial cell differentiation capability of triple negative breast carcinoma cells 191
Prevention of spontaneous mammary adenocarcinoma in HER-2/neu transgenic mice by foreign DNA 190
Influence of lignans depletion on murine mammary gland morphology 190
EGFR through STAT3 is a player in ΔNp63α expression and together sustain tumor-initiating cell proliferation in squamous cell carcinomas 190
Intestinal glucose uptake protects liver from lipopolysaccharide and d-galactosamine, acetaminophen, and alpha-amanitin in mice 187
SGLT-1 as a novel immunological player in the intestinal mucosa 187
TLR3 expression induces apoptosis in human non‐small‐cell lung cancer 187
Influence of antibiotic treatment on breast carcinoma development in proto-neu transgenic mice 186
Surveillance of spontaneous breast cancer metastasis by TRAIL-expressing CD34+ cells in a xenograft model 185
CpG-Oligodeoxynucleotides activate tyrosinase-related protein 2-specific T lymphocytes but do not lead to a protective tumor-specific memory response 184
Apoptosis of hair follicle cells during doxorubicin-induced alopecia in rats 181
Ascites regression and survival increase in mice bearing advanced-stage human ovarian carcinomas and repeatedly treated intraperitoneally with CpG-ODN 180
Reprogramming the lung microenvironment by inhaled immunotherapy fosters immune destruction of tumor 180
Eradication of ovarian tumor xenografts by locoregional administration of targeted immunotherapy 179
Fluctuation of HER2 expression in breast carcinomas during the menstrual cycle 177
Toll-like receptor agonists regulate beta-defensin 2 release in hair follicle 176
Targeting Local Microbiota by Antibiotic Therapy Promotes Immunosurveillance against Cancer 173
Dansyl C-glucoside as a novel agent against endotoxic shock 169
FOXP3 expression and overall survival in breast cancer 162
Linking survival of HER2-positive breast carcinoma patients with surgical invasiveness 162
Topical administration of a doxorubicin-specific monoclonal antibody prevents drug-induced mouth apoptosis in mice 162
Enhanced antitumour efficacy of gimatecan in combination with Bcl-2 antisense oligonucleotide in human melanoma xenografts 161
Apoptosis induction by trastuzumab: Possible role of the core biopsy intervention 161
Maspin influences response to doxorubicin by changing the tumor microenvironment organization 158
USO DI MONOSACCARIDI COME IMMUNOMODULANTI 156
COMPOSTI A STRUTTURA GLICOSIDICA ATTIVI NELLA TERAPIA DI STATI INFIAMMATORI LOCALI E SISTEMICI 154
Activity and resistance of trastuzumab according to different clinical settings 151
Biology, prognosis and response to therapy of breast carcinomas according to HER2 score 150
Cross-talk between tool-like receptors 5 and 9 on activation of human immune responses 150
HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancer 150
Low molecular weight hyaluronic acid increases the self defence of skin epithelium by induction of β-defensin 2 via TLR2 and 4 150
Relevant role of repeated intreperitoneally treatment with CpG-ODN in mice bearing advanced-stage of human ovarian carcinomas 149
AIRE is expressed and associated with good prognosis in breast cancer 144
Flow cytometric analysis of activation markers on stimulated T cells and their correlation with cell proliferation 143
Chemotherapy can enhance trastuzumab-mediated ADCC 142
Thymic function and immunoglobulin mutation genotype in B-cell chronic lymphocytic leukemia patients 138
Totale 25.050
Categoria #
all - tutte 77.647
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 77.647


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021705 0 0 0 0 0 0 0 0 0 0 529 176
2021/20222.748 220 174 148 188 260 219 232 235 255 181 228 408
2022/20232.835 341 326 229 311 322 482 69 169 305 57 110 114
2023/20242.150 137 219 153 217 341 127 121 159 83 147 216 230
2024/20254.332 201 386 161 398 285 237 213 486 319 343 383 920
2025/20267.690 784 453 781 641 877 568 1.051 454 899 543 639 0
Totale 31.058